Aton Pharma, Inc. Launches Authorized Generic Version of Glaucoma Eye Drop Timoptic-XE(R) Gel Forming Solution

LAWRENCEVILLE, N.J., March 9 /PRNewswire/ -- Aton Pharma, Inc., a diversified specialty pharmaceutical company, today announced that it has launched an authorized generic version of its Timoptic-XE(R) (timolol maleate ophthalmic gel forming solution). Timoptic-XE is a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. Aton also announced that it will continue to make available branded Timoptic-XE.

Aton's U.S. Timoptic product line includes Timoptic (timolol maleate) Ophthalmic Solution, Timoptic (timolol maleate ophthalmic solution) in Ocudose(R) (sterile ophthalmic unit dose dispenser) and Timoptic-XE (timolol maleate ophthalmic gel forming solution) Ophthalmic and now an authorized generic form of this branded product.

Timoptic is indicated for the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. Timoptic is contraindicated in patients with bronchial asthma; a history of bronchial asthma; severe chronic obstructive pulmonary disease; sinus bradycardia; second or third degree atrioventricular block; overt cardiac failure; cardiogenic shock; or hypersensitivity to any component of this product. Because of the potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical ophthalmic administration. The most frequent adverse events have been burning and stinging upon installation.

Aton Pharma, Inc.